Revenue
2022
2023
2024
2025
Coiled Therapeutics plc (COIL)
Price£0.0850Cached quote
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £200,000 | £0 |
| Gross profit | £0 | −£16,000 | £200,000 | £0 |
| Gross margin | — | — | 100.00% | — |
| Research & development | £149,529 | £152,915 | £620,159 | £319,315 |
| Operating expenses | £821,958 | £1.1M | £2.1M | £1.6M |
| Operating income | −£821,958 | −£1.1M | −£1.9M | −£1.6M |
| Operating margin | — | — | −966.82% | — |
| EBITDA | −£3.4M | −£1.2M | −£1.9M | −£1.6M |
| EBITDA margin | — | — | −964.14% | — |
| Net income | −£3.4M | −£971,803 | −£1.7M | −£1.6M |
| Net profit margin | — | — | −872.27% | — |
| Basic EPSper basic share | -£0.22 | -£0.08 | -£0.14 | -£0.16 |
| Diluted EPSper diluted share | -£0.22 | -£0.08 | -£0.14 | -£0.16 |
Owners
Reported ownership
Community posts
Coiled reports £3.85 million interim loss after oncology transformation
Coiled Therapeutics ($COIL) reported a first-half loss before tax of £3.85 million, compared with £0.53 million a year earlier, following its shift into clinical-stage oncology. Operating activities consumed £2.85 million of cash versus £0. ...
